Altimmune (ALT) Net Cash Flow (2010 - 2026)

Altimmune (ALT) has 17 years of Net Cash Flow data on file, last reported at $53.8 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $53.8 million, up 342.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.5 million (up 262.34% YoY), and the FY2025 annual result was $6.8 million, up 106.96% from the prior year.
• Net Cash Flow improved to $53.8 million in Q1 2026 per ALT's latest filing, from -$17.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $134.0 million in Q2 2025 and troughed at -$121.9 million in Q3 2025.
• A 5-year average of -$5.5 million and a median of -$10.4 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow sank 1202.89% in 2022, then surged 713.28% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$16.4 million in 2022, then jumped by 394.86% to $48.3 million in 2023, then plunged by 88.7% to $5.5 million in 2024, then slumped by 420.54% to -$17.5 million in 2025, then soared by 408.09% to $53.8 million in 2026.
• Business Quant data shows ALT's Net Cash Flow at $53.8 million in Q1 2026, -$17.5 million in Q4 2025, and -$121.9 million in Q3 2025.